WideMed has received the US Food and Drug Administration (FDA) approval for its portable home sleep diagnostic and monitoring solution Morpheus Ox.
Morpheus Ox is a watch-size device which provides automatic sleep diagnostics scoring from the photoplethysmography (PPG) signal and displays the results to the physicians.
The device uses automatic sleep scoring software and provides sleep study diagnosis, including Sleep/Wake, Apnea Hypopnea Index (AHI) and Cheyne-Stokes Breathing.
WideMed’s cellular application can record and transmit the data collected during the test.
The proprietary analysis derives a respiratory analyzed signal which is comparable to the measured respiratory signals acquired from full Polysomnography (PSG) sleep study.
The Morpheus Ox Web-based server software manages a sleep services operation, including cardiac and sleep diagnostics outcomes, patient’s electronic medical record, and a complete workflow management.
WideMed CEO Anya Eldan said its technology uses the PPG signal acquired from a standard pulse oximeter to enable a diagnostics of respiratory and cardiac clinical parameters.